Studies have shown that mutation in the IDH1 gene, especially the R132H mutation, can promote NK cell recruitment through CX3CL1/CX3CR1 chemotherapy and are associated with a better prognosis in gliomas (Ren et al., 2019). This evidence concerns the gene CX3CR1 and central nervous system cancer.